The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Contacts: InvestorsHeather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 MediaCarly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189
Source:
2022 GlobeNewswire, Inc., source